Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 58

1.

Soluble Tie2 and Flt1 extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy.

Harris AL, Reusch P, Barleon B, Hang C, Dobbs N, Marme D.

Clin Cancer Res. 2001 Jul;7(7):1992-7.

2.

A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis.

Braybrooke JP, O'Byrne KJ, Propper DJ, Blann A, Saunders M, Dobbs N, Han C, Woodhull J, Mitchell K, Crew J, Smith K, Stephens R, Ganesan TS, Talbot DC, Harris AL.

Clin Cancer Res. 2000 Dec;6(12):4697-704.

3.

High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer.

Foekens JA, Peters HA, Grebenchtchikov N, Look MP, Meijer-van Gelder ME, Geurts-Moespot A, van der Kwast TH, Sweep CG, Klijn JG.

Cancer Res. 2001 Jul 15;61(14):5407-14.

4.

Comparison of the prognosis indication of VEGFR-1 and VEGFR-2 and Tie2 receptor expression in breast carcinoma.

Meunier-Carpentier S, Dales JP, Djemli A, Garcia S, Bonnier P, Andrac-Meyer L, Lavaut MN, Allasia C, Charpin C.

Int J Oncol. 2005 Apr;26(4):977-84.

PMID:
15753992
5.

Serum levels of angiogenic factors and their prognostic relevance in bladder cancer.

Szarvas T, Jäger T, Droste F, Becker M, Kovalszky I, Romics I, Ergün S, Rübben H.

Pathol Oncol Res. 2009 Jun;15(2):193-201. doi: 10.1007/s12253-008-9107-z. Epub 2008 Sep 20.

PMID:
18807212
6.

Soluble Tie-2 receptor levels independently predict locoregional recurrence in head and neck squamous cell carcinoma.

Homer JJ, Greenman J, Drevs J, Marme D, Stafford ND.

Head Neck. 2002 Aug;24(8):773-8.

PMID:
12203803
7.

Vascular endothelial growth factor and soluble Tie-2 receptor in colorectal cancer: associations with disease recurrence.

Chin KF, Greenman J, Reusch P, Gardiner E, Marme D, Monson JR.

Eur J Surg Oncol. 2003 Aug;29(6):497-505.

PMID:
12875855
8.

Soluble VEGF/sFLt1 ratio is an independent predictor of AML patient out come.

Aref S, El Sherbiny M, Goda T, Fouda M, Al Askalany H, Abdalla D.

Hematology. 2005 Apr;10(2):131-4.

PMID:
16019458
10.

Synergy between tumor immunotherapy and antiangiogenic therapy.

Nair S, Boczkowski D, Moeller B, Dewhirst M, Vieweg J, Gilboa E.

Blood. 2003 Aug 1;102(3):964-71. Epub 2003 Apr 10.

11.

Angiogenesis and other markers for prediction of survival in metastatic renal cell carcinoma.

Alamdari FI, Rasmuson T, Grankvist K, Ljungberg B.

Scand J Urol Nephrol. 2007;41(1):5-9.

PMID:
17366095
12.

rAAV-mediated long-term liver-generated expression of an angiogenesis inhibitor can restrict renal tumor growth in mice.

Davidoff AM, Nathwani AC, Spurbeck WW, Ng CY, Zhou J, Vanin EF.

Cancer Res. 2002 Jun 1;62(11):3077-83.

13.

Expression of the angopoietin-1, angopoietin-2, Tie2, and vascular endothelial growth factor gene in epithelial ovarian cancer.

Hata K, Nakayama K, Fujiwaki R, Katabuchi H, Okamura H, Miyazaki K.

Gynecol Oncol. 2004 Apr;93(1):215-22.

PMID:
15047239
14.

Endothelial survival factors as targets for antineoplastic therapy.

Reinmuth N, Stoeltzing O, Liu W, Ahmad SA, Jung YD, Fan F, Parikh A, Ellis LM.

Cancer J. 2001 Nov-Dec;7 Suppl 3:S109-19. Review.

PMID:
11779081
15.

Antiangiogenic therapy in malignant glioma: promise and challenge.

Sathornsumetee S, Rich JN.

Curr Pharm Des. 2007;13(35):3545-58. Review.

PMID:
18220791
16.

Tie2/Tek expression in breast carcinoma: correlations of immunohistochemical assays and long-term follow-up in a series of 909 patients.

Dales JP, Garcia S, Bonnier P, Duffaud F, Meunier-Carpentier S, Andrac-Meyer L, Lavaut MN, Allasia C, Charpin C.

Int J Oncol. 2003 Feb;22(2):391-7.

PMID:
12527939
17.
18.

Prognostic and predictive value of vascular endothelial growth factor and its soluble receptors, VEGFR-1 and VEGFR-2 levels in the sera of small cell lung cancer patients.

Ustuner Z, Saip P, Yasasever V, Vural B, Yazar A, Bal C, Ozturk B, Ozbek U, Topuz E.

Med Oncol. 2008;25(4):394-9. doi: 10.1007/s12032-008-9052-4. Epub 2008 Mar 4.

PMID:
18317954
19.

Tie2 vascular endothelial receptor expression and function in hepatocellular carcinoma.

Tanaka S, Sugimachi K, Yamashita Yi Y, Ohga T, Shirabe K, Shimada M, Wands JR, Sugimachi K.

Hepatology. 2002 Apr;35(4):861-7.

PMID:
11915032
20.

Analysis of soluble angiogenic factors in Crohn's disease: a preliminary study.

Dueñas Pousa I, Maté Jiménez J, Salcedo Mora X, Abreu MT, Moreno Otero R, Gisbert JP.

Gastroenterol Hepatol. 2007 Nov;30(9):518-24. Erratum in: Gastroenterol Hepatol. 2008 Feb;31(2):74. Abreu, Maria T [corrected to Abreu, María T]; Gisber, Javier P [corrected to Gisbert, Javier P].

PMID:
17980128

Supplemental Content

Support Center